


PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/18, C12N 5/06, 5/08	A1	(11) International Publication Number: WO 99/12560 (43) International Publication Date: 18 March 1999 (18.03.99)
(21) International Application Number: PCT/US98/18772 (22) International Filing Date: 9 September 1998 (09.09.98) (30) Priority Data: 60/058,258 9 September 1997 (09.09.97) US (71) Applicant (for all designated States except US): CREATIVE BIOMOLECULES, INC. [US/US]; 45 South Street, Hopkinton, MA 01748 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): RUEGER, David, C. [US/US]; 81 Pine Hill Road, Southborough, MA 01772 (US). CHARETTE, Marc, F. [US/US]; 17 Ellicott Street, Needham, MA 02192 (US). EBENDAL, Ted [SE/SE]; Uppsala University, Dept. of Neurological Sciences, P.O. Box 587, BMC, S-751 23 Uppsala (SE). (74) Agent: TWOMEY, Michael, J.; Testa, Hurwitz & Thibault, LLP, High Street Tower, 125 High Street, Boston, MA 02110 (US).		(81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: SYNERGISTIC EFFECTS OF OP/BMP MORPHOGENS AND GDNF/NGF NEUROTROPHIC FACTORS		



(57) Abstract

A synergistic effect of OP/BMP morphogens in combination with GDNF/NGF neurotrophic factors in promoting the survival or growth, or inhibiting the death or degeneration, of mammalian cells, particularly neural cells, which express OP/BMP-activated serine/threonine kinase receptors and GDNF/NGF-activated tyrosine kinase receptors, is disclosed. Also disclosed are new methods for the *in vivo* and *in vitro* treatment of such cells, including *in vivo* treatments for mammals afflicted with, or at imminent risk of, damage or injury to such cells, as well as new pharmaceutical preparations for such *in vivo* and *in vitro* treatments.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

SYNERGISTIC EFFECTS OF OP/BMP MORPHOGENS AND GDNF/NGF NEUROTROPHIC FACTORS

Field of the Invention

The present invention relates generally to methods and preparations for the treatment of mammalian subjects afflicted with, or at imminent risk of, damage or injury to tissues, particularly neural tissues, which express receptors for OP/BMP morphogens and GDNF/NGF neurotrophic factors.

5

Background of the Invention

During development of the mammalian nervous system, differentiating neurons from the central and peripheral nervous systems send out axons that must grow and make contact with specific target cells. In some cases, neurons stay confined entirely within the central nervous system. In other cases, however, growing axons must cover enormous distances, extending from the CNS into the periphery of the body. In mammals, this stage of neurogenesis is completed during the embryonic phase of life and, it is believed, neuronal cells do not multiply once they have fully differentiated.

Dendritic growth occurs in two phases: initial extension followed by elongation and ramification. Purves *et al.*, Nature 336:123-128 (1988). Some molecules, including neurotransmitters and hormones, have been shown to regulate expansion of an existing dendritic arbor. Much less is known, however, about the factors that influence early events, and cause a neuron to initially form dendrites. In certain classes of neurons, initial dendritic sprouting occurs as part of an intrinsic developmental program which is relatively independent of trophic interactions. Dotti *et al.*, J. Neurosci. 8:1454-1468 (1988). In other classes of neurons, however, the regulation of the initial stages of dendritic growth appears to be quite different. For example, rat sympathetic neurons fail to form dendrites and extend only axons when they are cultured in the absence of non-neuronal cells. In contrast, co-culture with Schwann cells or astrocytes causes these neurons to form dendritic processes and to eventually generate a dendritic arbor which is comparable in size to that observed *in situ*. Tropea *et al.*, Glia 1:380-392 (1988). Thus, it would appear that specific trophic interactions are required to allow sympathetic neurons to form dendrites.

- 2 -

The foregoing observations have been taken to support a theory that the *in situ* environment specifies formation of a dendritic arbor. The environment in the vicinity of neural cells or developing neural processes is thought to include electromagnetic, electrochemical and/or biochemical fields or gradients which positively and negatively influence the extent and specificity of dendritic outgrowth as well as the formation of synapses between dendrites and nerve cell bodies and axons. This theory, however, suffers from a paucity of identified mediators which have the capacity to cause neurons to sprout dendrites.

A host of neuropathies, some of which affect only a subpopulation or a system of neurons in the peripheral or central nervous systems have been identified. The neuropathies, which may affect the neurons themselves or the associated glial cells, may result from cellular metabolic dysfunction, infection, exposure to toxic agents, autoimmunity dysfunction, malnutrition or ischemia. In some cases the cellular dysfunction is thought to induce cell death directly by apoptosis. Oppenheim, Ann Rev. Neurosci. 14:37-43 (1991). In other cases, the neuropathy may induce tissue necrosis by stimulating the body's immune system, resulting in a local inflammatory response and cell lysis at the initial site of neural injury.

The ability of neurons within the peripheral nervous system to regenerate a damaged neural pathway is limited. Specifically, new axons and dendrites extend randomly, and are often misdirected, making contact with inappropriate targets that can cause abnormal function. In addition, where severed nerve processes result in a gap of longer than a few millimeters, *e.g.*, greater than 10 millimeters (mm), appropriate nerve regeneration does not occur, either because the processes fail to grow the necessary distance, or because of misdirected axonal growth. Efforts to repair peripheral nerve damage by surgical means has met with mixed results, particularly where damage extends over a significant distance. In some cases, the suturing steps used to obtain proper alignment of severed nerve ends stimulates the formulation of scar tissue which is thought to inhibit axon regeneration. Even where scar tissue formation has been reduced, as with the use of nerve guidance channels or other tubular prostheses, successful regeneration generally is still limited to nerve damage of less than 10 millimeters in distance.

It is now well established that various trophic factors play a critical role in regulating the survival and differentiation of developing neurons. Snider *et al.*, Ann. Neurol. 26:489-506 (1989). Most of the characterized actions of nerve trophic actors relate to developmental events and suggest that the temporal and local regulation of expression of these proteins plays a role during maturation of the nervous system. Nerve trophic factors are also important in the function

- 3 -

of the adult nervous system for the maintenance of structural integrity and regulation of plasticity. Such processes are altered in neurodegenerative diseases and neurodegenerative events following acute injury to the nervous system. This has prompted speculation that nerve trophic factors are involved in the structural alterations which occur in response to injury and disease.

5 Several well-characterized trophic factors have been shown to enhance the survival and differentiation of dopaminergic neurons in tissue culture and/or following transplantation to the anterior chamber of the eye. These trophic factors include fibroblast growth factor (FGF), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), transforming growth factor- α (TGF- α), and glial cell-derived neurotrophic factor (GDNF), as well as several Nerve
10 Growth Factor (NGF) related neurotrophins.

Nerve trophic factors are found among several protein superfamilies of polypeptide growth factors based on their amino acid sequence homology and/or their three-dimensional structure. MacDonald *et al.*, Cell 73:421-424 (1993). One family of neurotrophic factors is the neurotrophin family. This family currently consists of Nerve Growth Factor (NGF), Brain
15 Derived Neurotrophic Factor (BDNF), Neurotrophin-3 (NT-3), Neurotrophin-4/5 (NT-4/5), and Neurotrophin-6 (NT-6). These neurotrophic factors affect specific neuronal populations in the central nervous system. The loss of such specific neurotrophic factors may be responsible for age-related declines in cell survival and/or function. While the cellular source remains unclear, there is evidence to suggest that neurons and glial cells are both capable of secreting neurotrophic
20 factors.

The osteogenic protein/bone morphogenetic protein (OP/BMP) proteins form a family, or subfamily, within the larger TGF- β superfamily of proteins. That is, these proteins form a distinct subgroup, referred to herein as the "OP/BMP family of morphogens" or "OP/BMP morphogens," within the loose evolutionary grouping of sequence-related proteins known as the TGF- β
25 superfamily. Members of this protein family comprise secreted polypeptides that share common structural features, and that are similarly processed from a pro-protein to yield a carboxy-terminal mature protein. OP/BMP morphogens have been identified in developing and adult rat brain and spinal cord tissue, as determined both by northern blot hybridization of morphogen-specific probes to mRNA extracts from developing and adult nerve tissue and by immunolocalization
30 studies. For example, northern blot analysis of developing rat tissue has identified significant OP-1 mRNA transcript expression in the CNS. The mRNA of another OP/BMP family member,

- 4 -

GDF-1, appears to be expressed primarily in developing and adult nerve tissue, specifically in the brain, including the cerebellum and brain stem, spinal cord and peripheral nerves. BMP4 (also referred to as BMP2B) and Vgr-1 transcripts also have been reported to be expressed in nerve tissue.

5 The morphogen OP-1 was found to be localized predominantly to the extracellular matrix of the grey matter (neuronal cell bodies), distinctly present in all areas except the cell bodies themselves. In white matter, formed mainly of myelinated nerve fibers, staining appears to be confined to astrocytes (glial cells). A similar staining pattern also was seen in newborn rat (10 day old) brain sections.

10 In addition, OP-1 has been specifically localized in the substantia nigra, which is composed primarily of striatal basal ganglia, a system of accessory motor neurons whose function is associated with the cerebral cortex and corticospinal system. Dysfunctions in this subpopulation or system of neurons are associated with a number of neuropathies, including Huntington's chorea and Parkinson's disease.

15 Summary of the Invention

The present invention is based, in part, upon the discovery that OP/BMP morphogens in combination with GDNF/NGF neurotrophic factors show a synergistic effect in promoting the survival or growth, or inhibiting the death or degeneration, of mammalian cells, particularly neural cells, which express OP/BMP-activated serine/threonine kinase receptors and GDNF/NGF-activated tyrosine kinase receptors. Based on this discovery, the present invention provides new methods for *in vivo* and *in vitro* treatment of such cells, including *in vivo* treatments for mammals afflicted with, or at imminent risk of, damage or injury to such cells, as well as new pharmaceutical preparations for such *in vivo* and *in vitro* treatments.

Thus, in one aspect, the present invention provides methods for promoting the survival or growth of mammalian cells, particularly neural cells, by contacting the cells with an effective concentration of a preparation comprising a GDNF/NGF neurotrophic factor and an OP/BMP morphogen. Similarly, the present invention provides methods for inhibiting the death or degeneration of mammalian cells, particularly neural cells, by contacting the cells with an effective concentration of a preparation comprising a GDNF/NGF neurotrophic factor and an OP/BMP morphogen. Such methods may be employed *in vitro* (e.g., for improved cell cultures) or *in vivo* (e.g., for treating conditions affecting such cells in a mammalian subject).

- 5 -

In another aspect, the present invention specifically provides methods for treating a mammalian subject afflicted with, or at imminent risk of, damage or injury to cells, particularly neural cells, comprising contacting the neural cells with an effective concentration of a preparation comprising a GDNF/NGF neurotrophic factor and an OP/BMP morphogen. These methods can be applied to either neurons or neuroglial cells, and to either central or peripheral nervous system cells.

The methods of the present invention are particularly suited to the treatment of cells which have been damaged or injured, or are at imminent risk of damage or injury, due to mechanical traumas such as blunt force traumatic brain injury, blunt force traumatic spinal cord injury, concussion, intracranial pressure due to cerebral edema or subdural haematoma, broken or crushed vertebra, and torn or severed nerves; chemical traumas such as those arising from exposure to neurotoxins or the side effects of chemotherapies; ischemic injuries such as those arising from stroke, cardiac arrest or failure; and neuropathic or neurodegenerative damage or injury such as those arising from neuropathic diseases including Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis, Alzheimer's disease, epilepsy, progressive muscular atrophy, Charcot-Marie-Tooth disease, palsy, dementia, Shy-Drager disease, Wernicke-Korsakoff syndrome, and Hallervorden-Spatz disease.

In preferred embodiments, the OP/BMP morphogens of the present invention comprise polypeptides having amino acid sequences with at least 70% homology, more preferably 80% homology, with the C-terminal seven-cysteine domain of human OP-1. In particularly preferred embodiments, the OP/BMP morphogens comprise polypeptides having at least 60% amino acid identity, more preferably at least 70% identity, with the C-terminal seven-cysteine domain of human OP-1. In most preferred embodiments, the OP/BMP morphogen comprises at least the C-terminal six- or seven-cysteine domain of a mammalian, preferably human, OP-1, OP-2, OP-3, BMP2, BMP3, BMP4, BMP5, BMP6, or BMP9 protein. Preferably, the OP/BMP morphogens of the present invention are capable of inducing osteogenesis in the Reddi-Sampath ectopic bone assay.

In preferred embodiments, the GDNF/NGF neurotrophic factors of the present invention comprise at least the mature, functional form of a mammalian, preferably human, GDNF, NGF, BDNF, NT-3, NT-4, NT-5 or NT-6 protein.

- 6 -

In preferred embodiments the effective concentration of the preparation comprises between 0.1 ng/ml and 10 µg/ml of an OP/BMP morphogen and between 0.1 ng/ml and 10 µg/ml of a GDNF/NGF neurotrophic factor, more preferably between 1 ng/ml and 100 ng/ml of either an OP/BMP morphogen or a GDNF/NGF neurotrophic factor and, most preferably, between 1
5 ng/ml and 100 ng/ml of both an OP/BMP morphogen and a GDNF/NGF neurotrophic factor.

In another aspect, the present invention provides methods for promoting the survival or growth, or inhibiting the death or degeneration, of mammalian cells, including non-neural cells, which express an OP/BMP-activated serine/threonine kinase receptor and a GDNF/NGF-activated tyrosine kinase receptor. Similarly, the present invention provides methods for treating
10 a mammalian subject afflicted with damage or injury to cells, or at imminent risk of damage or injury to cells, including non-neural cells, which express an OP/BMP-activated serine/threonine kinase receptor and a GDNF/NGF-activated tyrosine kinase receptor. These methods also comprise contacting such cells with an effective concentration of a preparation comprising a GDNF/NGF neurotrophic factor and an OP/BMP morphogen, as described above.

15 In another aspect, the present invention provides for pharmaceutical preparations for promoting the survival or growth of mammalian cells, or inhibiting the death or degeneration of mammalian cells, particularly neural cells, comprising a GDNF/NGF neurotrophic factor in combination with an OP/BMP morphogen.

The preferred methods, materials, and examples that will now be described are illustrative
20 only and are not intended to be limiting. Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.

Brief Description of the Drawings

FIG. 1 is a bar graph showing the survival of dissociated sympathetic neurons grown in collagen gels after 2 or 6 day treatment with NT-3 (2 ng/ml) or GDNF (50 ng/ml), in the presence
25 or absence of OP-1.

Detailed Description of the Invention

The present invention provides new methods of treatment for mammalian subjects afflicted with, or at imminent risk of, damage or injury to tissues, particularly neural tissues, comprising the administration of a combination of an OP/BMP morphogen and a GDNF/NGF neurotrophic
30 factor. Surprisingly, it has been demonstrated that administration of these agents in combination

- 7 -

has a synergistic effect in promoting the survival and/or growth of neural tissues, and in inhibiting death or degeneration of neural tissues. In addition, the present invention provides new pharmaceutical preparations comprising an OP/BMP morphogen in combination with a GDNF/NGF neurotrophic factor.

5 Without being bound to any particular theory of the invention, it is believed that the OP/BMP morphogens and GDNF/NGF neurotrophic factors exert a synergistic effect in promoting the survival and/or growth of neural tissues, and in inhibiting death or degeneration of neural tissues, by acting through separate receptor-based signaling pathways. In particular, it is believed that the OP/BMP proteins act through serine/threonine kinase receptors and that the
10 GDNF/NGF neurotrophic factors of the invention act through tyrosine kinase receptors such that, when an OP/BMP morphogen and a GDNF/NGF neurotrophic factor are administered in combination, both the serine/threonine kinase and the tyrosine kinase signal transduction pathways are activated and a synergistic effect is produced.

Thus, the OP/BMP morphogens have been shown to act through serine/threonine kinase
15 receptors, and these receptors have been shown to be expressed in both peripheral and central nervous system tissues. For example, it has been shown by *in situ* hybridization that several classes of peripheral neurons express BMP type II serine/threonine kinase receptors known to bind members of the OP/BMP morphogen family (Liu *et al.*, Mol. Cell. Biol. 15:3479-3486 (1995); Rosenzweig *et al.*, Proc. Natl. Acad. Sci. (USA) 92:7632-7636 (1995)), and that both
20 OP/BMP type I and type II serine/threonine receptors are expressed in the CNS. Söderström *et al.*, Cell Tiss. Res. 286:269-279 (1996a); Nosrat *et al.*, Cell Tiss. Res. 286:191-207 (1996).

Similarly, the GDNF/NGF neurotrophic factors have been shown to act through specific tyrosine kinase receptors which are expressed in neural tissues. Thus, for example, the signaling pathway of GDNF has been shown to involve the activation of the tyrosine kinase receptor Ret
25 (Trupp *et al.*, Nature 381:785-789 (1996)), which is expressed in neural tissues including sympathetic, nodose and ciliary ganglia. Similarly, NT-3 acts via the TrkC receptor and, to some extent, via the TrkA receptor. See, *e.g.*, Ebendal, J. Neurosci. Res. 32:461-470 (1992). These receptors are expressed in the brain and spinal cord as well as peripheral neurons. See, *e.g.*, Vazquez and Ebendal, Neuro Report 2:593-596 (1991); Pei and Ebendal, Exp. Neurol. 132:105-
30 115 (1995); Söderström *et al.*, Dev. Brain Res. 85:96-108 (1995); Hallböök *et al.*, Int. J. Dev. Biol. 39: 855-868 (1995); Williams and Ebendal, Neuro Report 6:2277-2282 (1995); Williams *et al.*, Eur. J. Neurosci. 7:116-128 (1995).

- 8 -

Thus, in one aspect, the present invention provides methods of promoting the survival and/or growth of neural tissues, or of inhibiting death or degeneration of neural tissues, by administering to a mammal an OP/BMP morphogen and a GDNF/NGF neurotrophic factor in combination, thereby activating both the OP/BMP-activated serine/threonine kinase pathway and the

5 GDNF/NT-activated tyrosine kinase pathway. In another aspect, the present invention provides for new pharmaceutical preparations for use in promoting the survival and/or growth of neural tissues, or of inhibiting death or degeneration of neural tissues, and comprising an OP/BMP morphogen and a GDNF/NGF neurotrophic factor in combination.

In another aspect, the present invention provides methods and pharmaceutical preparations

10 for the treatment of non-neural tissues. In particular, there are a variety of non-neural tissues which express OP/BMP-activated serine/threonine kinase receptors and GDNF-activated tyrosine kinase receptors, including renal tissue and many thyroid papillary carcinomas (see, *e.g.*, Schuchardt *et al.*, Nature 367: 380-383 (1994); Pachnis *et al.*, Development 119:1005-1017 (1993)). Therefore, the present invention also provides methods of promoting the survival and/or

15 growth of such non-neural tissues, or of inhibiting death or degeneration of such non-neural tissues, by administering to a mammal an OP/BMP morphogen and a GDNF/NGF neurotrophic factor in combination, thereby activating both the OP/BMP-activated serine/threonine kinase pathway and the GDNF/NT-activated tyrosine kinase pathway. Similarly, the present invention provides for new pharmaceutical preparations for use in promoting the survival and/or growth of

20 such non-neural tissues, or of inhibiting death or degeneration of such non-neural tissues, and comprising an OP/BMP morphogen and a GDNF/NGF neurotrophic factor in combination.

A. OP/BMP Morphogens

The OP/BMP morphogens of the present invention are naturally occurring proteins, or functional variants of naturally occurring proteins, in the osteogenic protein/bone morphogenetic

25 protein (OP/BMP) family within the TGF- β superfamily of proteins. That is, these proteins form a distinct subgroup, referred to herein as the "OP/BMP morphogens," within the loose evolutionary grouping of sequence-related proteins known as the TGF- β superfamily. Members of this protein family comprise secreted polypeptides that share common structural features, and that are similarly processed from a pro-protein to yield a carboxy-terminal mature protein. Within

30 the mature protein, all members share a conserved pattern of six or seven cysteine residues defining a 97-106 amino acid domain, and the active form of these proteins is either a disulfide-

- 9 -

bonded homodimer of a single family member, or a heterodimer of two different members. See, e.g., Massague, Annu. Rev. Cell Biol. 6:597 (1990); Sampath *et al.*, J. Biol. Chem. 265:13198 (1990). For example, in its mature, native form, natural-sourced human OP-1 is a glycosylated dimer typically having an apparent molecular weight of about 30-36 kDa as determined by

5 SDS-PAGE. When reduced, the 30 kDa protein gives rise to two glycosylated peptide subunits having apparent molecular weights of about 16 kDa and 18 kDa. The unglycosylated protein has an apparent molecular weight of about 27 kDa. When reduced, the 27 kDa protein gives rise to two unglycosylated polypeptide chains, having molecular weights of about 14 kDa to 16 kDa.

Typically, the naturally occurring OP/BMP proteins are translated as a precursor, having

10 an N-terminal signal peptide sequence, a "pro" domain, and a "mature" protein domain. The signal peptide is typically less than 30 residues, and is cleaved rapidly upon translation at a cleavage site that can be predicted using the method of Von Heijne, Nucleic Acids Research 14:4683-4691 (1986). The "pro" domain is variable both in sequence and in length, ranging from approximately 200 to over 400 residues. The pro domain is cleaved to yield the "mature"

15 C-terminal domain of approximately 115-180 residues, which includes the conserved six- or seven-cysteine C-terminal domain of 97-106 residues. As used herein, the "pro form" of an OP/BMP family member includes a protein comprising a folded pair of polypeptides, each comprising a pro domain in either covalent or noncovalent association with the mature domains of the OP/BMP polypeptide. Typically, the pro form of the protein is more soluble than the mature

20 form under physiological conditions. The pro form appears to be the primary form secreted from cultured mammalian cells. The "mature form" of the protein includes a mature C-terminal domain which is not associated, either covalently or noncovalently, with the pro domain. Any preparation of OP-1 is considered to contain mature form when the amount of pro domain in the preparation is no more than 5% of the amount of "mature" C-terminal domain.

25 OP/BMP family members useful herein include any of the known naturally-occurring native proteins including allelic, phylogenetic counterpart and other variants thereof, whether naturally-sourced or biosynthetically produced (e.g., including "muteins" or "mutant proteins"), as well as new, active members of the OP/BMP family of proteins.

Particularly useful sequences include those comprising the C-terminal seven cysteine

30 domains of mammalian, preferably human, human OP-1, OP-2, OP-3, BMP2, BMP3, BMP4, BMP5, BMP6, BMP8 and BMP9. Other proteins useful in the practice of the invention include

- 10 -

active forms of GDF-5, GDF-6, GDF-7, DPP, Vgl, Vgr-1, 60A, GDF-1, GDF-3, GDF-5, GDF-6, GDF-7, BMP10, BMP11, BMP13, BMP15, UNIVIN, NODAL, SCREW, ADMP or NURAL and amino acid sequence variants thereof. In one currently preferred embodiment, the OP/BMP morphogens of the invention are selected from any one of: OP-1, OP-2, OP-3, BMP2, BMP3, BMP4, BMP5, BMP6, and BMP9.

Publications disclosing these sequences, as well as their chemical and physical properties, include: OP-1 and OP-2: U.S. Pat. No. 5,011,691, U.S. Pat. No. 5,266,683, and Ozkaynak *et al.*, EMBO J. 9:2085-2093 (1990); OP-3: WO94/10203; BMP2, BMP3, and BMP4: U.S. Pat. No. 5,013,649, WO91/18098, WO88/00205, and Wozney *et al.*, Science 242:1528-1534 (1988); BMP5 and BMP6: WO90/11366 and Celeste *et al.*, Proc. Natl. Acad. Sci. (USA) 87:9843-9847 (1991); Vgr-1: Lyons *et al.*, Proc. Natl. Acad. Sci. (USA) 86: 4554-4558 (1989); DPP: Padgett *et al.*, Nature 325:81-84 (1987); Vgl: Weeks, Cell 51:861-867 (1987); BMP9: WO95/33830; BMP10: WO94/26893; BMP-11: WO94/26892; BMP12: WO95/16035; BMP-13: WO95/16035; GDF-1: WO92/00382 and Lee *et al.*, Proc. Natl. Acad. Sci. (USA) 88:4250-4254 (1991); GDF-8: WO94/21681; GDF-9: WO94/15966; GDF-10: WO95/10539; GDF-11: WO96/01845; BMP-15: WO96/36710; MP121: WO96/01316; GDF-5 (CDMP-1, MP52): WO94/15949, WO96/14335, WO93/16099 and Storm *et al.*, Nature 368:639-643 (1994); GDF-6 (CDMP-2, BMP13): WO95/01801, WO96/14335 and WO95/10635; GDF-7 (CDMP-3, BMP12): WO95/10802 and WO95/10635; BMP-3b: Takao *et al.*, Biochem. Biophys. Res. Comm. 219:656-662 (1996); GDF-3: WO94/15965; 60A: Basler *et al.*, Cell 73:687-702 (1993) and GenBank Accession No. L12032. In another embodiment, useful proteins include biologically active biosynthetic constructs, including novel biosynthetic proteins and chimeric proteins designed using sequences from two or more known OP/BMP family proteins. See also the biosynthetic constructs disclosed in U.S. Pat. No. 5,011,691, the disclosure of which is incorporated herein by reference (*e.g.*, COP-1, COP-3, COP-4, COP-5, COP-7, and COP-16).

In other preferred embodiments, the OP/BMP morphogens useful herein include proteins which comprise an amino acid sequence sharing at least 70% amino acid sequence "homology" and, preferably, 75% or 80% homology with the C-terminal seven cysteine domain present in the active forms of human OP-1 (*i.e.*, residues 330-431, as shown in SEQ ID NO: 2 of U.S. Pat. No. 5,266,683). In other preferred embodiments, the OP/BMP morphogens useful herein include proteins which comprise an amino acid sequence sharing at least 60% amino acid sequence identity and, preferably, 65% or 70% identity with the C-terminal seven cysteine domain present

- 11 -

in the active forms of human OP-1. Thus, a candidate amino acid sequence can be aligned with the amino acid sequence of the C-terminal seven cysteine domain of human OP-1 using the method of Needleman *et al.*, J. Mol. Biol. 48:443-453 (1970), implemented conveniently by computer programs such as the Align program (DNASTar, Inc.). As will be understood by those skilled in the art, homologous or functionally equivalent sequences include functionally equivalent arrangements of the cysteine residues within the conserved cysteine skeleton, including amino acid insertions or deletions which alter the linear arrangement of these cysteines, but do not materially impair their relationship in the folded structure of the dimeric protein, including their ability to form such intra- or inter-chain disulfide bonds as may be necessary for biological activity.

Therefore, internal gaps and amino acid insertions in the candidate sequence are ignored for purposes of calculating the level of amino acid sequence homology or identity between the candidate and reference sequences.

"Amino acid sequence homology" is understood herein to include both amino acid sequence identity and similarity. Thus, as used herein, a percentage "homology" between two amino acid sequences indicates the percentage of amino acid residues which are identical or similar between the sequences. "Similar" residues are "conservative substitutions" which fulfill the criteria defined for an "accepted point mutation" in Dayhoff *et al.*, Atlas of Protein Sequence and Structure Vol. 5 (Suppl. 3), pp. 354-352 (1978), Natl. Biomed. Res. Found., Washington, D.C. Thus, "conservative amino acid substitutions" are residues that are physically or functionally similar to the corresponding reference residues, having similar size, shape, electric charge, and/or chemical properties such as the ability to form covalent or hydrogen bonds, or the like. Examples of conservative substitutions include the substitution of one amino acid for another with similar characteristics, *e.g.*, substitutions within the following groups: (a) valine, glycine; (b) glycine, alanine; (c) valine, isoleucine, leucine; (d) aspartic acid, glutamic acid; (e) asparagine, glutamine; (f) serine, threonine; (g) lysine, arginine, methionine; and (h) phenylalanine, tyrosine. The term "conservative substitution" or "conservative variation" also includes the use of a substituted amino acid in place of an unsubstituted parent amino acid in a given polypeptide chain, provided that the resulting substituted polypeptide chain has biological activity useful in the present invention.

The OP/BMP morphogens of the invention are characterized by biological activities which may be readily ascertained by those of ordinary skill in the art. Specifically, an OP/BMP morphogen of the present invention is capable of inducing osteogenesis in the Reddi-Sampath

- 12 -

ectopic bone assay (Sampath and Reddi, Proc. Natl. Acad. Sci. (USA) 78:7599-7603 (1981)) or a substantially equivalent assay.

The Reddi-Sampath ectopic bone assay is well known in the art as an assay of osteogenic activity. The assay, which can be easily performed, is described and discussed in, for example, Sampath and Reddi, Proc. Natl. Acad. Sci. (USA) 78:7599-7603 (1981); and Wozney, "Bone Morphogenetic Proteins," Progress in Growth Factor Research 1:267-280 (1989). Many equivalent assays, using other animals and tissue sites, may be employed or developed by those of skill in the art to evaluate the biological activity of the OP/BMP morphogens of the present invention. See, for example, the bioassays described in U.S. Pat. No. 5,226,683.

The OP/BMP morphogens contemplated herein can be expressed from intact or truncated genomic or cDNA or from synthetic DNAs in prokaryotic or eukaryotic host cells. The dimeric proteins can be isolated from the culture media and/or refolded and dimerized *in vitro* to form biologically active preparations. Heterodimers can be formed *in vitro* by combining separate, distinct polypeptide chains. Alternatively, heterodimers can be formed in a single cell by co-expressing nucleic acids encoding separate, distinct polypeptide chains. See, for example, WO93/09229, or U.S. Pat. No. 5,411,941, for several exemplary recombinant heterodimer protein production protocols. Currently preferred host cells include, without limitation, prokaryotes including E. coli, or eukaryotes including yeast such as Saccharomyces, insect cells, or mammalian cells, such as CHO, COS or BSC cells. One of ordinary skill in the art will appreciate that other host cells can be used to advantage. Detailed descriptions of the proteins useful in the practice of this invention, including how to make, use and test them for osteogenic activity, are disclosed in numerous publications, including U.S. Pat. Nos. 5,266,683 and 5,011,691, the disclosures of which are herein incorporated by reference.

B. GDNF/NGF Neurotrophic Factors

The GDNF/NGF neurotrophic factors useful in the methods and preparations of the present invention include polypeptides, as well as functional variants of polypeptides, comprising at least the active portion of a mature mammalian protein selected from the group consisting of GDNF, BDNF, NGF, NT-3, NT-4, NT-5 and NT-6. Each of these preferred GDNF/NGF neurotrophic factors is discussed separately below.

1. GDNF. Glial cell-derived neurotrophic factor (GDNF) is a neurotrophic factor that belongs to the transforming growth factor- β (TGF- β) superfamily, but not to the OP/BMP family

- 13 -

within the TGF- β superfamily. GDNF displays potent survival and differentiation-promoting effects for dopaminergic neurons both *in vitro*. Lin *et al.*, Science 260:1130-1132 (1993)) and *in vivo* in animal models (Hudson *et al.*, Brain Res. Bull. 36:425-432 (1995); Hoffer *et al.*, Neurosci. Lett. 182:107-111 (1994). GDNF has also been shown to have neurotrophic effects for

5 cholinergic motor neurons of the brain stem and spinal cord. Oppenheim *et al.*, Nature 373:344-346 (1995); Yan *et al.*, Nature 373:341-344 (1995). Descriptions of the active portion of a mature mammalian GDNF protein can be found in, for example, Lin *et al.*, Science 260:1130-1132 (1993); Lin *et al.*, J. Neurochem. 63: 758-768 (1994); and PCT Publication WO97/11965. In brief, GDNF is synthesized as a precursor and secreted as a mature protein comprising 134

10 amino acids, including the seven cysteine domain which characterizes the TGF- β superfamily of proteins. A 133 amino acid variant of GDNF in which the initial Met residue has been omitted ([Met⁻¹]GDNF) has substantially equivalent biological activity. See, *e.g.*, WO97/11965. As used herein, the term "GDNF" includes a polypeptide comprising at least the 134 amino acid mature form, as well as a functional variant of the polypeptide, such as a conservative amino acid

15 substitution variant or the 133 amino acid variant.

2. NGF. Nerve growth factor (NGF) is the best characterized member of the "neurotrophin" protein family, other members of which include brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), neurotrophin-4 (NT-4), neurotrophin-5 (NT-5), and neurotrophin-6 (NT-6), discussed below. NGF has been shown to play a role in the regulation of

20 the initial stages of dendritic growth, and to aid in promoting the survival, growth and/or repair of cholinergic neurons, and maintaining the differentiated phenotype of cholinergic neurons. For example, NGF can cause a subpopulation of nodose neurons to form dendrites in culture (De Koninck *et al.*, J. Neurosci. 13:577-585 (1993)) and can enhance the growth of sympathetic dendrites when injected *in situ* (Snider, J. Neurosci. 8:2628-2634 (1988)). NGF alone, however,

25 does not support dendritic growth in cultures of sympathetic neurons. Bruckenstein and Higgins, Dev. Biol. 128:324-336 (1988). In addition, NGF has been shown to be effective in preventing or even reversing the atrophy of cholinergic neurons induced in a standard fimbria/fornix axotomy model of Alzheimer's Disease. See, *e.g.*, Batchelor *et al.*, J. Comp. Neurol. 284:187-204 (1989); Hefti *et al.*, J. Neurobiol. 25:1418-1435 (1994); Olson *et al.*, Neurochem. J. 25:1-3 (1994). As

30 used herein, the term "NGF" includes a polypeptide comprising at least the mature form, as well as a functional variant of the polypeptide, such as a conservative amino acid substitution variant.

- 14 -

3. BDNF. Brain-derived neurotrophic factor (BDNF), another member of the neurotrophin family of proteins, has been shown to enhance dopamine uptake by fetal nigral DA neurons in cell culture (Beck *et al.*, Neurosci. 52:855-866 (1993); Knusel *et al.*, Proc. Natl. Acad. Sci. (USA) 88:961-969 (1991)) and to partially protect DA neurons from the toxic effects of the neurotoxins N-methyl-4-phenylpyridinium ion and 6-hydroxydopamine (6-ODHA). Hyman *et al.*, Nature 350:230-232 (1991). BDNF has also been shown to have a strong supportive effect on the survival of cultured nigral DA neurons. Beck *et al.*, Neurosci. 52:855-866 (1993); Hyman *et al.*, Nature 350:230-232 (1991); Knusel *et al.*, Proc. Natl. Acad. Sci. (USA) 88:961-965 (1991). These findings suggested that BDNF might have a survival-promoting effect on grafted DA neurons *in vivo*. BDNF treatment enhances the behavioral effect of grafted nigral DA neurons to the DA-depleted striatum of unilaterally 6-ODHA-lesioned rats as manifested by a relative reduction in amphetamine-induced turning at two weeks post-grafting. Sauer *et al.*, Brain Research 626:37-44 (1993). However, this study failed to establish any clear cut difference between treated and control animals in the extent of neurite outgrowth from the grafted DA neurons. Thus, although infusion with BDNF produced several behavioral and morphological effects in rats grafted with fetal nigral tissue, it was unable to increase the survival rates of the transplanted dopamine cells. As used herein, the term "BDNF" includes a polypeptide comprising at least the mature form, as well as a functional variant of the polypeptide, such as a conservative amino acid substitution variant.
4. NT-3. As used herein, "NT-3" means a human protein, or mammalian homologues thereof, having a protein sequence essentially as published at Jones *et al.*, Proc. Natl. Acad. Sci. (USA) 87:8060-8064 (1990); Maisonpierre *et al.*, Genomics 10:558-568 (1991); Kaisho *et al.*, FEBS Lett. 266:187-191 (1990); WO 91/03569; and available through GenBank Accession No. M37763. The isolation and/or characterization of human NT-3 is described in, for example, Jones *et al.*, Proc. Natl. Acad. Sci. (USA) 87:8060-806 (1990); and Maisonpierre *et al.*, Science 247:1446-1451 (1990). The mouse NT-3 sequence is disclosed in Hohne *et al.*, Nature 344:339-341 (1990); WO 91/03569, and GenBank Accession No. X53257. The rat NT-3 gene sequence is disclosed in Ernfors *et al.*, Proc. Natl. Acad. Sci. (USA) 87:5454-5458 (1990); WO 91/03569; and GenBank Accession No. M34643. Comparison of the human NT-3 precursor to the rat and mouse NT-3 precursors reveals that the mature forms are identical. The gene for human NT-3 encodes a putative 257 amino acid precursor with an 18 amino acid signal peptide which is processed to a 119 amino acid mature peptide. NT-3 RNA has been detected in human CNS

- 15 -

tissues including the cerebellum, nucleus basalis, basal ganglia, hippocampus and visual cortex. Maisonpierre *et al.*, Genomics 10:558-568 (1991). Human NT-3 shares 56% amino acid identity with human NGF and human BDNF, and shares the conserved 6 cysteine with other members of the neurotrophin family, with the regions of greatest homology between the three proteins being clustered around these cysteine residues. The term "NT-3," as used herein, includes a polypeptide comprising at least the mature 119 amino acid form as disclosed in Jones *et al.*, Proc. Natl. Acad. Sci. (USA) 87:8060-806 (1990), as well as a functional variant of the polypeptide, such as a conservative amino acid substitution variant.

5. NT-4. As used herein, "NT-4" means a human protein, or mammalian homologues thereof, having a protein sequence essentially as published at Ip *et al.*, Proc. Natl. Acad. Sci. (USA) 89:3060-3064 (1992); U.S. Pat. No. 5,364,769; and available through GenBank Accession No. M86528. The isolation and/or characterization of NT-4 is described in, for example, Ip *et al.*, Proc. Natl. Acad. Sci. (USA) 89:3060-3064 (1992); Hallböök *et al.*, Neuron 6:845-858 (1991); and Ibanez *et al.*, Development 117:1345-1353 (1993). The complete NT-4 gene sequence encodes a 236 amino acid, 27 kD precursor protein comprising a putative signal peptide sequence and pro- region of approximately 60 amino acids, which is believed to be processed to a 130 amino acid mature human NT-4 polypeptide. The mature form of NT-4 shares 46.5%, 55.4% and 52.2% sequence identity with NGF, BDNF, and NT-3, respectively. NT-4 contains the conserved 6 cysteines of the neurotrophin family, but contains a seven amino acid insertion located between the second and third cysteines. NT-4 has been demonstrated to support the survival of neurons of the trigeminal ganglion in the mouse (Ibanez *et al.*, Development 117:1345-1353 (1993)) and dorsal root ganglia in the chicken (Ip *et al.*, Proc. Natl. Acad. Sci. (USA) 89:3060-3064 (1992)). In the rat, NT-4 mRNA has been found in spinal cord and several brain regions including cerebellum and cortex. The term "NT-4," as used herein, includes a polypeptide comprising at least the mature 130 amino acid form as disclosed in Ip *et al.*, Proc. Natl. Acad. Sci. (USA) 89:3060-3064 (1992), as well as a functional variant of the polypeptide, such as a conservative amino acid substitution variant.

6. NT-5. As used herein, the term "NT-5" means a human protein, or mammalian homologue thereof, having a protein sequence essentially as described in Berkemeier *et al.*, Neuron 7:857-866 (1991). The isolation and/or characterization of NT-5 is described in, for example, Berkemeier *et al.*, Neuron 7:857-866 (1991) and Berkemeier *et al.*, Som. Cell Mol. Genet. 18:233-245 (1992). The human gene for NT-5 encodes a putative 210 amino acid, 22.4

- 16 -

kD precursor protein. The assigned initiation codon is followed by a putative signal sequence cleavage site at Ser - 24. The putative pre-pro sequence of NT-5 is approximately 50 amino acids shorter than those of the other neurotrophins. The overall homology of the NT-5 precursor with Xenopus NT-4, human NT-3, human BDNF and human NGF is 52%, 45%, 47% and 41%, respectively. The mature NT-5 is 123 amino acids long and shares the 6 cysteines conserved in the neurotrophin family. NT-5 shares 50% homology with NGF, 56% homology with BDNF, 55% homology with NT-3 and 66% homology with Xenopus NT-4. The rat NT-5 gene encodes a 209 amino acid protein that is 91% identical to its human counterpart. Berkemeier *et al.*, Neuron 7:857-866 (1991). NT-5 protein has been identified in adult rat brain, and acts as a survival factor for dorsal root ganglion sensory cells and promotes survival and neurite outgrowth from sympathetic ganglion neurons. Berkemeier *et al.*, Neuron 7:857-866 (1991). The term "NT-5," as used herein, includes a polypeptide comprising the mature 123 amino acid form, as well as a functional variant of the polypeptide, such as a conservative amino acid substitution variant.

7. NT-6. As used herein, "NT-6" means a human protein, or mammalian homologue thereof, having a protein sequence essentially as described in Gotz *et al.*, Nature 327:266-269; WO 95/26363 (1994); and available through GenBank Accession Nos. L36325 and L36942. The isolation and characterization of NT-6 is described in, for example, Gotz *et al.*, Nature 327:266-269 (1994). The NT-6 precursor contains 286 amino acids, having a hydrophobic domain at the N terminus (residues 1-19) characteristic of a signal peptide, and a putative pro- region at residues 20-142. The putative mature protein begins at residue 143. NT-6 shares the conserved 6 cysteines found in all neurotrophins, but contains a 22 residue insert between the second and third conserved cysteine containing domain. The term "NT-6," as used herein, includes a polypeptide comprising the mature 119 amino acid form disclosed in Gotz *et al.*, Nature 327:266-269 (1994), as well as a functional variant of the polypeptide, such as a conservative amino acid substitution variant.

C. Subjects for Treatment

Subjects for treatment according to the methods of the present invention include, without limitation, (1) those having neural tissues which have been damaged, or are at imminent risk of damage, due to mechanical traumas such as arise from blunt force traumas to the head, cerebral edema, subdural haematoma, broken or crushed vertebra, or torn or severed nerves (including those arising from surgical procedures); (2) those which have suffered, or are at imminent risk of

- 17 -

suffering, chemical traumas to nervous tissue as may arise, for example, from exposure to neurotoxins (*e.g.*, lead, ethanol, ammonia, formaldehyde, mercury) or the administration of chemotherapeutic agents with neurotoxic side effects (*e.g.*, cisplatin); (3) those which have suffered, or are at imminent risk of, an ischemic injury to neural tissues (*e.g.*, cerebral stroke); and
5 (4) those afflicted with, or at imminent risk of, a neuropathy or neurodegenerative disease.

Particularly contemplated is the treatment of human subjects diagnosed with, or at imminent risk of, a neuropathy or neurodegenerative disease selected from the group consisting of amyotrophic lateral sclerosis (ALS), progressive muscular atrophy, hereditary motor and sensory neuropathy (Charcot-Marie-Tooth disease), Alzheimer's Disease, epilepsy, Huntington's Disease, Parkinson's
10 Disease, palsy, dementia, Shy-Drager disease, Wernicke-Korsakoff syndrome, and Hallervorden-Spatz disease.

Diseases such as ALS, progressive muscular atrophy, and hereditary motor and sensory neuropathy (Charcot-Marie-Tooth disease) all result, at least in part, from degeneration of motor neurons which are located in the ventral horn of the spinal cord. Thus, in one embodiment, the
15 present invention provides for methods and preparations which employ an OP/BMP morphogen in combination with a GDNF/NGF neurotrophic factor for the treatment of these and other conditions involving loss of or damage to motor neurons.

The hippocampus, a well-defined structure that is part of the cerebral cortex of the brain, is important in the formation of long term memory. Degeneration of pyramidal CA1 neurons, which
20 are located in the CA1 region of the hippocampus, is one characteristic of Alzheimer's disease. These same neurons are selectively vulnerable to ischemic and anoxic damage which occurs in conditions such as stroke and head trauma. In addition, the CA1 pyramidal hippocampal neurons as well as pyramidal neurons located in the CA3 region of the hippocampus are selectively injured in epilepsy. Thus, in one embodiment, the present invention provides for methods and
25 preparations which employ an OP/BMP morphogen in combination with a GDNF/NGF neurotrophic factor for the treatment of these and other conditions involving loss of or damage to hippocampal neurons.

The majority of neurons in the striatum utilize GABA (4-aminobutyric acid) as their neurotransmitter, and may be referred to as "GABAergic" neurons. The striatum is also the
30 major target of the progressive neurodegeneration that occurs in Huntington's disease, in which striatal GABA-utilizing neurons (*e.g.*, spiny cell neurons and enkephalin neurons) atrophy and/or

- 18 -

die. Thus, in one embodiment, the present invention provides for methods and preparations which employ an OP/BMP morphogen in combination with a GDNF/NGF neurotrophic factor for the treatment of this and other conditions involving loss of or damage to striatal or GABAergic neurons.

5 Dopamine-producing ("dopaminergic" or "DA") neurons are located primarily in the substantia nigra and, to a lesser extent, in the adjacent striatum (comprising the caudate nucleus, putamen, pallidum and locus coeruleus). The neurons of the striatum express receptors for dopamine and are responsible for control of motor activity. Thus, degeneration of DA neurons results in a decrease of dopamine levels and loss of motor activity. In particular, the progressive
10 degeneration of dopaminergic neurons in the substantia nigra can lead to the slowing of initiation and execution of voluntary muscle movement (bradykinesia), the muscular rigidity, and tremor which are characteristic of Parkinson's Disease. Thus, in one embodiment, the present invention provides for methods and preparations which employ an OP/BMP morphogen in combination with a GDNF/NGF neurotrophic factor for the treatment of this and other conditions involving
15 loss of or damage to dopaminergic neurons, including those of the substantia nigra.

Other neuropathic conditions in which populations of neural cells are lost or damaged include palsy, dementia, Shy-Drager disease, Wernicke-Korsakoff syndrome, and Hallervorden-Spatz disease. Thus, in other embodiments, the present invention provides for methods and preparations which employ an OP/BMP morphogen in combination with a GDNF/NGF
20 neurotrophic factor for the treatment of these and other conditions involving loss of or damage to neural tissues.

D. Pharmaceutical Preparations

The pharmaceutical preparations of the present invention include at least one OP/BMP morphogen in combination with at least one GDNF/NGF neurotrophic factor. Preferably, such
25 preparations include an amount of each agent which is effective when administered by alone. Because of the synergistic effect of the agents in combination, however, the pharmaceutical preparations may contain an amount of each agent which, when administered in the absence of the other, would not be effective alone. The determinations of appropriate ratios of the agents is within the ability and discretion of one of ordinary skill in the art for the treatment of a given
30 condition, for a given combination of OP/BMP morphogen and GDNF/NGF neurotrophic factor, and given route of administration.

- 19 -

As a general matter, the pharmaceutical preparations of the present invention, including at least one OP/BMP morphogen and at least one GDNF/NGF neurotrophic factor can be tested using *in vitro* assays, animal models, and clinical studies. Effective concentrations of the preparations are those sufficient to (1) cause enhanced neurite outgrowth in an *in vitro* assay of neuronal growth; (2) cause motor skill improvements in a standard animal model of Parkinson's disease; or (3) cause a clinically significant improvement in neurological function when administered to a mammalian subject (*e.g.*, a human patient).

E. Methods and Formulations for Administration

The pharmaceutical preparations of the present invention, including at least one OP/BMP morphogen and at least one GDNF/NGF neurotrophic factor, can be administered to an individual by any suitable means, preferably directly (*e.g.*, locally, as by injection to a tissue locus) or systemically (*e.g.*, parenterally or orally). Where the preparation is to be administered parenterally, such as by intravenous, subcutaneous, intramuscular, intraorbital, ophthalmic, intraventricular, intracranial, intracapsular, intraspinal, intracisternal, intraperitoneal, or buccal administration, the preparation preferably comprises part of an aqueous solution. The solution is chosen to be physiologically acceptable such that, in addition to delivery of the desired OP/BMP morphogen and GDNF/NGF neurotrophic factor to the patient, the solution does not otherwise adversely affect the patient's electrolyte and volume balance.

Useful solutions for parenteral administration can be prepared by a variety of methods well known in the pharmaceutical arts. See, *e.g.*, Remington's Pharmaceutical Sciences, Gennaro, A., ed., Mack Pub., (1990). Formulations can include, for example, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, hydrogenated naphthalenes, and the like. Formulations for direct administration, in particular, can include glycerol and other preparations of high viscosity. Biocompatible, preferably bioresorbable, polymers, including, for example, hyaluronic acid, collagen, polybutyrate, tricalcium phosphate, lactide and lactide/glycolide copolymers, can be useful excipients to control the release of the preparation *in vivo*. Other potentially useful parenteral delivery systems for these preparations include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes.

As will be appreciated by those skilled in the art, the amounts and/or concentrations of the agents present in a pharmaceutical preparation will vary depending upon a number of factors, including the dosage of the drug to be administered, the chemical characteristics (*e.g.*,

- 20 -

hydrophobicity) of the agents employed, and the route of administration. The preferred dosage may also depend on such variables as the type and extent of the damage or injury to be treated, the overall health status of the subject, the relative biological efficacy of the agents employed, the presence of excipients or diluents, and the like.

5 As a general matter, the pharmaceutical preparations of the present invention are administered in amounts sufficient to achieve effective concentrations of the OP/BMP morphogen and the GDNF neurotrophic factor at a site of neural tissue damage or injury, or at a site of imminent risk of such injury. Preferably, the preparations contain an amount of an OP/BMP morphogen such that, when administered by the chosen route of administration, results in a
10 concentration of the OP/BMP morphogen of about 0.1 ng/ml to 10 µg/ml, more preferably about 1 ng/ml to 100 ng/ml. Similarly, the preparations preferably contain an amount of a GDNF/NGF neurotrophic factor such that, when administered by the chosen route of administration, results in a concentration of the GDNF/NGF neurotrophic factor of about 0.1 ng/ml to 10 µg/ml, more preferably about 1 ng/ml to 100 ng/ml. Because of the synergistic interactions of the OP/BMP
15 morphogens and GDNF/NGF neurotrophic factors, optimal concentrations and ratios will vary depending upon the particular agents employed.

Where injury to neurons of a neural pathway is induced deliberately as part of, for example, a surgical procedure, the OP/BMP morphogen and GDNF/NGF neurotrophic factor preferably are provided just prior to, or concomitant with induction of the trauma. Preferably, the morphogen
20 and neurotrophic factor are administered prophylactically in a surgical setting.

Where the OP/BMP morphogen and neurotrophic factor are to be provided to a site to stimulate axon regeneration, the pharmaceutical preparation preferably is provided to the site in association with a biocompatible, preferably bioresorbable carrier suitable for maintaining the proteins at the site *in vivo*, and through which a neural process can regenerate. A currently
25 preferred carrier also comprises sufficient structure to assist direction of axonal growth. Currently preferred carriers include structural molecules such as collagen, hyaluronic acid or laminin, and/or synthetic polymers or copolymers of, for example, polylactic acid, polyglycolic acid or polybutyric acid. Currently most preferred are carriers comprising tissue extracellular matrix. These can be obtained commercially. In addition, a brain tissue-derived extracellular
30 matrix can be prepared as described in PCT Publication WO92/15323, incorporated herein by reference, and/or by other means known in the art.

- 21 -

The currently preferred means for repairing breaks in neural pathways, particularly pathways of the peripheral nervous system, include providing the OP/BMP morphogen and GDNF/NGF neurotrophic factor to the site as part of a device that includes a biocompatible membrane or casing of a dimension sufficient to span the break and having openings adapted to receive severed nerve ends. The OP/BMP morphogen and GDNF/NGF neurotrophic factor are disposed within the casing, preferably dispersed throughout a suitable carrier, and are accessible to the severed nerve ends. Alternatively, the OP/BMP morphogen and GDNF/NGF neurotrophic factor can be adsorbed onto the interior surface of the casing, or otherwise associated therewith. The casing acts as a nerve guidance channel, aiding in directing axonal growth. Suitable channel or casing materials include silicone or bioresorbable materials such as collagen, hyaluronic acid, laminin, polylactic acid, polyglycolic acid, polybutyric acid and the like.

Examples

OP/BMP Morphogen and GDNF/NGF Neurotrophic Factor Synergy

The OP/BMP morphogen and GDNF/NGF neurotrophic factor compositions described herein enhance process formation in neural cells. A variety of peripheral ganglia derived from embryonic chickens were used as a model for the induction of nerve fiber outgrowth by OP-1 (Creative Biomolecules, Hopkinton, MA) in combination with GDNF (PeproTech, Rocky Hill, New Jersey), NT-3 (Austral Biologicals, San Ramon, CA), activin A (Austral Biologicals, San Ramon, CA), or mouse β -NGF.

Peripheral ganglia were obtained from embryonic day 9 (E9) chickens according to the method of Ebendal *et al.* (Ebendal, in IBRO Handbook series: Methods in the Neurosciences Vol. 12, pp. 81-93 (1989), John Wiley, Chichester). Sympathetic ganglia were obtained from the lumbar region. Ciliary ganglia were obtained from the orbit. Remak ganglia were obtained from the dorsal mesorectum. Dorsal root ganglia were obtained from the lumbo-sacral region. Nodose ganglia were obtained from the vagus nerve cranial to the heart. For some experiments, trigeminal ganglia were obtained and the maxillomandibular and ophthalmic lobes were separated before explantation. The ganglia were removed intact and maintained at 37°C with 5% CO₂ in a collagen matrix or were dissociated into single neurons and spread into a thin collagen gel (Ebendal (1989), *supra*). In both instances, the gels were supplemented with equal volumes of Eagle's Basal Medium with 1% fetal calf serum. Control cultures consisted of Eagle's Basal Medium with 1% fetal calf serum, in some instances supplemented with the buffer (25 mM

- 22 -

arginine, 150 mM NaCl, pH 9.0, 0.1% Tween 80) at concentrations to match the experimental culture dilutions. Cultures were treated with control medium, OP-1, NT-3, GDNF or NGF alone, or in various combinations and at a series of concentrations for 2, 4 and 6 days.

The 6 day cultures were fed with fresh medium containing the growth factors at day 4 post incubation. Whole ganglia were examined under dark-field illumination whereas dissociated neurons were examined using phase-contrast optics. Surviving cells were counted in a strip across the plate to calculate the survival relative to the survival of cells treated with NGF at 5 ng/ml for 2 days.

Previous studies have shown that NT-3 evokes fiber outgrowth in explanted ciliary ganglia and also elicits a weak response in sympathetic ganglia of the chicken embryo. Ernfors *et al.*, Proc. Natl. Acad. Sci. (USA) 87:5454-5458 (1990). OP-1 greatly enhanced fiber outgrowth induced by NT-3 treatment in E9 sympathetic ganglia. The effects were apparent after 2 days in culture and persisted after 4 days of culture. Optimal concentrations of NT-3 and OP-1 were 10 ng/ml and 50 ng/ml, respectively. Treatment of ganglia cultures with OP-1 in combination with GDNF gave similar results. OP-1 did not stimulate fiber outgrowth of any of the whole explanted E9 ganglia at doses of 0.1 ng/ml to 1000 ng/ml. Further, OP-1 also failed to stimulate younger ganglia (*e.g.*, from embryonic day 4.5). The buffer (pH 9) failed to exert any potentiating effect on the NT-3 responses in sympathetic, ciliary or nodose ganglia.

Treatment of ciliary ganglia with 10 ng/ml NT-3 and 50 ng/ml OP-1 resulted in robust fiber halos consisting of thick fascicles of neurites which radiated from the cell. Treatment of ciliary ganglia with 50 ng/ml GDNF and 50 ng/ml OP-1 gave a fiber halo of ciliary nerve fascicles after 2 days of culture. Ciliary ganglia extended fewer or less robust nerve fibers in response to NT-3 (2 ng/ml and 10 ng/ml) and GDNF (50 ng/ml) but did not extend neurites in response to 50 ng/ml OP-1 alone.

Thus treatment of neurons with a combination of OP-1 and NT-3, or OP-1 and GDNF, suggested a synergistic effect of OP-1 on NT-3 or GDNF induced neurite outgrowth. A statistical analysis also shows differences in survival to be significant (Figure 1) as compared with the control (BME, or Basal Medium, Eagle's). Both OP-1 and NT-3 are required from the beginning of the treatment period to elicit the enhanced nerve outgrowth response in the ciliary ganglia.

- 23 -

Sensory neurons of the nodose ganglia were also treated with OP-1 (50 ng/ml) alone and in combination with NT-3 (2 ng/ml and 10 ng/ml) or OP-1 (50 ng/ml) in combination with GDNF (50 ng/ml). Treatment of sensory neurons with OP-1 alone did not elicit fiber outgrowth. However, OP-1 enhanced NT-3 -induced neurite outgrowth after 2 and 4 days of treatment.

5 Activin A (20 ng/ml) did not mimic the effects of OP-1 when tested alone or in combination with NT-3 (10 ng/ml), GDNF (50 ng/ml) or NGF (5 ng/ml) in the treatment of sympathetic ganglia.

OP-1 is therefore capable of promoting NT-3 and GDNF induced nerve process formation in several classes of peripheral neurons.

10 Treatments for Alzheimer's Disease

Alzheimer's disease is a neurodegenerative disease in which there is significant neuronal loss of the large pyramidal cells of the parietal and frontal association areas, hippocampus and amagdyla. Cholinergic neurons of the basal forebrain and noradrenergic neurons of the locus coeruleus are also severely affected.

15 In accordance with the present invention, an OP/BMP morphogen, preferably human OP-1, is administered to an Alzheimer's patient in combination with a GDNF/NGF neurotrophic factor, preferably GDNF or NT-3, in order to promote the growth and survival of cells in this region, as well as to inhibit the progressive loss of additional neuronal cells.

An aqueous, pharmaceutical preparation comprising an OP/BMP morphogen and
20 GDNF/NGF neurotrophic factor is administered to the patient parenterally. Preferably, the preparation is administered intracerebrally by, for example, intracerebroventricular or intrathecal injection or infusion. In one embodiment, the cranium of the subject is immobilized in a stereotaxic device, a small hole is made in the skull, and the preparation is injected or infused directly into the affected regions of the brain. Dosages may be calculated to achieve
25 concentrations of the OP/BMP morphogen and GDNF/NGF neurotrophic factor of about 0.1-10 µg/ml, preferably about 1-100 ng/ml at the site of injection. Alternatively, dosages may be calculated to deliver about 10-100 µg/kg of the morphogen and neurotrophic factor, preferably 1-25 µg/kg. Dosages are repeated daily or less frequently for a period of several weeks to months or, if needed, on a regular basis throughout the life of the subject. Alternatively, a sustained
30 release device is implanted within the brain of the subject to cause a continuous release of the preparation over an extended period.

- 24 -

Treatments for Severed Nerve Fibers

Due to the limited ability of mammalian nerve cells grow or regenerate, severed nerve fibers frequently lead to permanent loss of the sensory or motor function associated with the nerve. Nerve fibers may be torn or severed in accidents (*e.g.*, vehicular accidents) or as an unavoidable
5 side effect of surgery.

In accordance with the present invention, an OP/BMP morphogen, preferably human OP-1, is administered in combination with a GDNF/NGF neurotrophic factor, preferably GDNF or NT-3, to a subject having severed nerve fibers in order to promote reparative growth and survival of the damaged cells.

10 An aqueous, pharmaceutical preparation comprising an OP/BMP morphogen and GDNF/NGF neurotrophic factor is administered to the patient parenterally. In the case of damaged peripheral nerve fibers (*e.g.*, in the sciatic nerve), the preparation is preferably administered in conjunction with the use of nerve guide channels which enclose the ends of the severed fibers and guide their growth together. In the case of severed fibers in the spinal cord, the
15 preparation is preferably injected or infused into the CSF in the region of the injury. Dosages may be calculated to achieve concentrations of the OP/BMP morphogen and GDNF/NGF neurotrophic factor of about 0.1-10 $\mu\text{g/ml}$, preferably about 1-100 ng/ml at the site of injection or infusion. Alternatively, dosages may be calculated to deliver about 10-100 $\mu\text{g/kg}$ of the morphogen and neurotrophic factor, preferably 1-25 $\mu\text{g/kg}$. In the case of a spinal injury, dosages
20 are repeated daily or less frequently for a period of several weeks to months. Alternatively, in the case of severed peripheral nerves enclosed in nerve guidance channels, a sustained release formulation is employed in which the preparation is admixed with a matrix material within the nerve guidance channel.

Treatments for Stroke

25 Ischemic events, or strokes, in the brain may cause neural lesions which result in permanent loss of cognitive, sensory, or motor function. Immediately after the onset of a stroke, inhibition of the death or degeneration of cells in the ischemic area, as well as the promotion of growth and survival of these cells, is important to minimizing permanent damage.

In accordance with the present invention, an OP/BMP morphogen, preferably human OP-1,
30 is administered in combination with a GDNF/NGF neurotrophic factor, preferably GDNF or NT-3, to a subject suffering from a stroke.

- 25 -

An aqueous, pharmaceutical preparation comprising an OP/BMP morphogen and GDNF/NGF neurotrophic factor is administered to the patient parenterally. Preferably, the preparation is administered intracerebrally by, for example, intracerebroventricular or intrathecal injection or infusion. Dosages may be calculated to achieve concentrations of the OP/BMP morphogen and GDNF/NGF neurotrophic factor of about 0.1-10 $\mu\text{g/ml}$, preferably about 1-100 ng/ml at the site of injection. Alternatively, dosages may be calculated to deliver about 10-100 $\mu\text{g/kg}$ of the morphogen and neurotrophic factor, preferably 1-25 $\mu\text{g/kg}$. Dosages may be continuous or frequent for a period of several days to weeks. First dosages are preferably administered within the first few hours on the onset of the stroke.

- 26 -

CLAIMS

What is claimed is:

- 1 1. A method for promoting growth of mammalian neural cells comprising:
2 contacting neural cells with a preparation comprising
3 (a) a morphogen comprising a dimeric protein having an amino acid sequence
4 with at least 70% homology with the C-terminal seven cysteine skeleton of human OP-1,
5 and
6 (b) a GDNF/NGF neurotrophic factor.
- 1 2. A method for inhibiting the degeneration of mammalian neural cells comprising:
2 contacting neural cells with a preparation comprising
3 (a) a morphogen comprising a dimeric protein having an amino acid sequence
4 with at least 70% homology with the C-terminal seven cysteine skeleton of human OP-1,
5 and
6 (b) a GDNF/NGF neurotrophic factor.
- 1 3. A method for treating a mammalian subject afflicted with damage or injury to neural cells
2 comprising:
3 contacting neural cells with a preparation comprising
4 (a) a morphogen comprising a dimeric protein having an amino acid sequence
5 with at least 70% homology with the C-terminal seven cysteine skeleton of human OP-1,
6 and
7 (b) a GDNF/NGF neurotrophic factor.
- 1 4. A method for treating a mammalian subject at imminent risk of damage or injury to neural
2 cells comprising:
3 contacting said neural cells with an effective concentration of a preparation comprising
4 (a) a GDNF/NGF neurotrophic factor, and
5 (b) an OP/BMP morphogen.
- 1 5. A method as in any one of claims 3-4 wherein said damage or injury comprises a
2 mechanical trauma to a tissue comprising said cells.
- 1 6. A method as in claim 5 wherein said mechanical trauma is selected from the group
2 consisting of blunt force traumatic brain injury, blunt force traumatic spinal cord injury,

- 27 -

3 concussion, intracranial pressure due to cerebral edema or subdural haematoma, broken or
4 crushed vertebra, and torn or severed nerves.

1 7. A method as in any one of claims 3-4 wherein said damage or injury comprises a chemical
2 trauma to a tissue comprising said cells.

1 8. A method as in any one of claims 3-4 wherein said damage or injury comprises ischemia of
2 a tissue comprising said cells.

1 9. A method as in any one of claims 3-4 wherein said damage or injury results from a
2 neuropathic disease.

1 10. A method as in claim 9 wherein said neuropathic disease is selected from the group
2 consisting of Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis,
3 Alzheimer's disease, epilepsy, progressive muscular atrophy, Charcot-Marie-Tooth disease, palsy,
4 dementia, Shy-Drager disease, Wernicke-Korsakoff syndrome, and Hallervorden-Spatz disease.

1 11. A method as in any one of claims 1-4 wherein said neural cells comprise neurons or
2 neuroglial cells.

1 12. A method as in any one of claims 1-4 wherein said neural cells comprise central nervous
2 system neural cells.

1 13. A method as in any one of claims 1-4 wherein said neural cells comprise peripheral
2 nervous system cells.

1 14. A method as in any one of claims 1-4 wherein said OP/BMP morphogen comprises an
2 amino acid sequence having at least 70% homology with the C-terminal seven-cysteine domain of
3 human OP-1.

1 15. A method as in claim 14 wherein said OP/BMP morphogen comprises an amino acid
2 sequence having at least 80% homology with the C-terminal seven-cysteine domain of human OP-
3 1.

1 16. A method as in claim 14 wherein said OP/BMP morphogen comprises an amino acid
2 sequence having at least than 60% amino acid identity with the C-terminal seven-cysteine domain
3 of human OP-1.

- 28 -

- 1 17. A method as in claim 14 wherein said OP/BMP morphogen comprises an amino acid
2 sequence having at least than 70% amino acid identity with the C-terminal seven-cysteine domain
3 of human OP-1.
- 1 18. A method as in claim 14 wherein said OP/BMP morphogen comprises at least the C-
2 terminal six- or seven-cysteine domain of a mammalian protein selected from the group consisting
3 of OP-1, OP-2, OP-3, BMP2, BMP3, BMP4, BMP5, BMP6, and BMP9.
- 1 19. A method as in any one of claims 1-4 wherein said effective concentration is between 0.1
2 ng/ml and 10 µg/ml of said OP/BMP morphogen and between 0.1 ng/ml and 10 µg/ml of said
3 GDNF/NGF neurotrophic factor.
- 1 20. A method as in claim 19 wherein said effective concentration is between 1 ng/ml and 100
2 ng/ml of said OP/BMP morphogen.
- 1 21. A method as in claim 19 wherein said effective concentration is between 1 ng/ml and 100
2 ng/ml of said GDNF/NGF neurotrophic factor.
- 1 22. A method as in claim 19 wherein said effective concentration is between 1 ng/ml and 100
2 ng/ml of said OP/BMP morphogen and between 1 ng/ml and 100 ng/ml of said GDNF/NGF
3 neurotrophic factor.
- 1 23. A method as in any one of claims 1-4 wherein said GDNF/NGF neurotrophic factor
2 comprises a mature, functional form of a protein selected from the group consisting of GDNF,
3 NGF, BDNF, NT-3, NT-4, NT-5 and NT-6.
- 1 24. A method for promoting the survival or growth of mammalian cells, wherein said cells
2 express an OP/BMP-activated serine/threonine kinase receptor and a GDNF/NGF-activated
3 tyrosine kinase receptor, comprising
4 contacting said cells with an effective concentration of a preparation comprising:
5 (a) a GDNF/NGF neurotrophic factor, and
6 (b) an OP/BMP morphogen.
- 1 25. A method for inhibiting the death or degeneration of mammalian cells, wherein said cells
2 express an OP/BMP-activated serine/threonine kinase receptor and a GDNF/NGF-activated
3 tyrosine kinase receptor, comprising
4 contacting said cells with an effective concentration of a preparation comprising:

- 29 -

5 (a) a GDNF/NGF neurotrophic factor, and

6 (b) an OP/BMP morphogen.

1 26. A method for treating a mammalian subject afflicted with damage or injury to cells,
2 wherein said cells express an OP/BMP-activated serine/threonine kinase receptor and a
3 GDNF/NGF-activated tyrosine kinase receptor, comprising

4 contacting said cells with an effective concentration of a preparation comprising:

5 (a) a GDNF/NGF neurotrophic factor, and

6 (b) an OP/BMP morphogen.

1 27. A method for treating a mammalian subject at imminent risk of damage or injury to cells,
2 wherein said cells express an OP/BMP-activated serine/threonine kinase receptor and a
3 GDNF/NGF-activated tyrosine kinase receptor, comprising

4 contacting said cells with an effective concentration of a preparation comprising:

5 (a) a GDNF/NGF neurotrophic factor, and

6 (b) an OP/BMP morphogen.

1 28. A pharmaceutical preparation for promoting the survival or growth of mammalian neural
2 cells comprising:

3 (a) a GDNF/NGF neurotrophic factor, and

4 (b) an OP/BMP morphogen.

1 29. A pharmaceutical preparation for inhibiting the death or degeneration of mammalian
2 neural cells comprising:

3 (a) a GDNF/NGF neurotrophic factor, and

4 (b) an OP/BMP morphogen.

1/1

FIGURE 1A





FIGURE 1B



INTERNATIONAL SEARCH REPORT

Int. .tional Application No

PCT/US 98/18772

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K38/18 C12N5/06 C12N5/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	P. DURBEC ET AL.: "GDNF SIGNALLING THROUGH THE Ret RECEPTOR TYROSINE KINASE." NATURE, vol. 381, 27 June 1996, pages 789-793, XP002092160 LONDON GB see page 791, left-hand column, paragraph 2 - page 792, left-hand column; figure 4 ---	1-29
Y	WO 97 21447 A (STRYCKER CORPORATION) 19 June 1997 see page 14, line 25 - page 15, line 18; claims 1-3,6-11,13,18-23,55-57; example 13; tables 60-66 see page 30, line 26 - page 31, line 36 see page 61, line 30 - page 6, line 18 --- -/--	1-29

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

3 February 1999

Date of mailing of the international search report

18/02/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Ryckebosch, A

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/18772

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>P. LEIN ET AL.: "THE EFFECTS OF EXTRACELLULAR MATRIX AND OSTEOGENIC PROTEIN-1 ON THE MORPHOLOGICAL DIFFERENTIATION OF RAT SYMPATHETIC NEURONS." INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE, vol. 14, no. 3, 1996, pages 203-215, XP002092161 OXFORD, GB see page 213, line 38 - page 214, line 3</p>	1-29
Y	<p>WO 96 18735 A (AMGEN BOULDER INC.) 20 June 1996 see page 2, line 28 - page 3, line 22; claims</p>	1-29
A	<p>P. LEIN ET AL.: "OSTEOGENIC PROTEIN-1 INDUCES DENDRITIC GROWTH IN RAT SYMPATHETIC NEURONS." NEURON, vol. 15, no. 3, September 1995, pages 597-605, XP002092162 CAMBRIDGE MA, US see page 600, right-hand column, paragraph 2 - page 601, right-hand column, paragraph 2; figure 4</p>	1-29
A	<p>I. LOMKO: "NEUROTROPHINS - AN UPDATE" DRUG NEWS AND PERSPECTIVES, vol. 6, no. 9, November 1993, pages 669-671, XP000647898 see table I</p>	1-29
P,X	<p>H. BENGTSSON ET AL.: "POTENTIATING INTERACTIONS BETWEEN MORPHOGENETIC PROTEIN AND NEUROTROPHIC FACTORS IN DEVELOPING NEURONS." JOURNAL OF NEUROSCIENCE RESEARCH, vol. 53, no. 5, 1 September 1998, pages 559-568, XP002092163 NEW YORK, N.Y., US see the whole document</p>	1-29

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/ 18772

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 1,2,11-25 (all in as far as being related to an in vivo method) and 3-10,26 and 27 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking(Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/18772

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9721447 A	19-06-1997	AU 1333297 A	03-07-1997
		CA 2238277 A	19-06-1997
		EP 0871471 A	21-10-1998
		US 5854207 A	29-12-1998
WO 9618735 A	20-06-1996	AU 4424996 A	03-07-1996